Login to Your Account

Vernalis, Endo Pact: $400M Potential For Migraine Drug

By Randall Osborne

Wednesday, July 21, 2004
For the second time in as many months, London-based Vernalis plc reached across the ocean for a major deal with a U.S. firm, entering this week an agreement worth up to $400 million with pain-drug specialist Endo Pharmaceuticals Inc. focused on the migraine therapy Frova. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription